Role of erythropoietin in methotrexate-induced nephrotoxicity in adult male albino rats

Ahmed Hassan Al-Rashidy1,2,*, Rasha Rabea Salem3,4, Amal Abdelrasool Alhosary5,6, Mohamed Hassan Wahdan7,8, Gamal Mohamed Elnemr9,10, Khalid Ebraheem Hassan11, Atif Ibrahim Ali12

1Department of Pathology, College of Medicine, Taif University, Kingdom of Saudi Arabia
2Department of Pathology, Faculty of Medicine (Assiut), Al-Azhar University, Egypt
3Department of Anatomy and Embryology, College of Medicine, Taif University, Kingdom of Saudi Arabia
4Department of Anatomy and Embryology, Faculty of Medicine, Alexandria University, Egypt
5Department of Clinical Pathology, College of Medicine (Female), Taif University, Kingdom of Saudi Arabia
6Department of Clinical Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
7Department of Anatomy and Embryology, College of Medicine, Taif University, Kingdom of Saudi Arabia
8Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Egypt
9Department of Internal Medicine, College of Medicine, Taif University, Kingdom of Saudi Arabia
10Department of Medical and Radiological Researches, Nuclear Materials Authority, Egypt
11Department of Pathology, College of Medicine, Taif University, Kingdom of Saudi Arabia
12Department of Histology, Faculty of Medicine (Cairo), Al-Azhar University, Egypt

ABSTRACT

Introduction: Methotrexate (MTX) could provoke a renal dysfunction. However, beneficial extra-hematopoietic effect of erythropoietin might guard against MTX-induced nephrotoxicity. Objectives: Determination of renoprotective erythropoietin’s role against MTX-induced nephrotoxicity through elucidating its renofunctional and renomorphological effects in adult male albino rats.

Materials and Methods: The study was performed on 60 adult male Albino rats, equally divided into three groups; group 1 (control): treated with intraperitoneal injections of normal saline at a dosage of 0.5 mg/kg BW twice weekly for 9 weeks. group 2: injected with MTX hydrate intraperitoneal twice weekly at a dosage of 0.5 mg/kg BW for 9 weeks; and group 3: intraperitoneal injected with MTX hydrate in a similar dosage and duration like group 2 concomitant with subcutaneous injection of 100 IU/kg recombinant human erythropoietin once weekly for 9 weeks. At the study end, serum urea and creatinine together with albuminuria were measured, rats were sacrificed and renal sections were prepared for histopathological examination.

Results: Significantly increased values of renal function analyzed substances with deteriorated histopathological renal changes were detected in the MTX-treated group compared to either the control or to the MTX and erythropoietin co-treated group. The later displayed statistically significant decreased levels of the substances accompanied by remarkably ameliorated microscopic renal changes. Additionally, insignificant statistical biochemical and morphological renal differences were noticed between the third and control groups.

Conclusion: This study concluded valuable and efficient defense against MTX-induced nephrotoxicity in adult male Albino rats when co-treated with erythropoietin.

Implication for health policy/practice/research/medical education: Our study revealed that MTX had produced both renal functional and structural impairment. However, concomitant administration of erythropoietin with MTX had protected the kidneys both biochemically and histopathologically.


*Corresponding author: Ahmed Hassan Al-Rashidy, Email: dr.ahmed_elrashedy@yahoo.com
Erythropoietin and methotrexate nephrotoxicity

Introduction

Anticancer therapy may be chased with kidney damage exemplified by disturbed tubular and/or glomerular function (1,2). Common unfavorable renal effects of childhood cancer chemotherapy include acute renal injury, tubulointerstitial disorder, capillary endothelial damage and electrolytes as well as acid-base disturbances (3). Renal disorders occurring with chemotherapeutic drugs are caused by low renal blood supply, tubular obstruction, renal parenchymal and microvascular structural damage (4-6).

One of the broadly used anticancer drugs is methotrexate (MTX) that acts as a typical anti-folate. A large dose of MTX is called high-dose MTX (HDMTX) which is given by delayed i.v. infusion in the patients with the normal renal function following an excess fluid intake and alkalinization to obtain the drug solubility in urine. Co-administration of leucovorin greatly protects against fatal MTX toxicity (7). However, MTX-induced nephrotoxicity endures even though infrequently with these protective measures. Since MTX is removed through excretion from the kidney, however, MTX-induced renal disturbed function is associated with an interrupted MTX removal resulting in continuous elevation of its plasma concentration with a subsequent obvious development of MTX-toxic manifestations predominantly myelosuppression as well as hepatic, cutaneous and mucosal inflammation (8). Moreover, a lot of drugs such as nonsteroidal anti-inflammatory, penicillin, probenecid, and sulfisoxazole when concomitantly given with MTX, they have been accompanied by enhanced nephrotoxicity due to their interference with excretion of MTX from the kidney and by challenging in the renal tubular secretion (7). Development of MTX- induced renal dysfunction is indicated by sudden elevation of serum creatinine together with a significant increase of the concentration of MTX in the plasma (9,10). Furthermore, a significant hepatic dysfunction associating HDMTX therapy has not essentially been accompanied by renal failure development (7).

Erythropoietin (EPO) considered as a growth factor, is crucial in cell proliferation and neovascularization. In addition, EPO biochemically is a glycoprotein released by interstitial cells, found in a soluble form in the circulation, and promotes erythropoiesis. It largely treats anemic patients with the end-stage kidney disorder and patients with allograft kidney (11-13). Moreover, it is applied to guard renal tissue against reperfusion damage (14). EPO is recently evidenced to have several additional biological tasks that can keep several organs including the kidney in case of ischemic renal injury (IRI) despite the actual molecular pathogenesis of EPO self-protective effect remains indistinct (15). However, toll-like receptors (TLRs) are thought to be the keystone molecules in the regulation of inflammatory responses. Also, significantly increased expression of TLR4 from the renal tubular epithelial cells is confirmed and therefore, it activates the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and helps the expression of various inflammatory factors detected in IRI (16).

One of the essential side effects of oncotherapeutic drugs is nephrotoxicity that is distinguished by a diminished glomerular filtration rate and renal blood supply (17,18). The ameliorating and defensive effect of EPO against cisplatin-induced nephrotoxicity was stated in female (19) and male (20) rats as well as in other experimental animals (20-22).

Objectives

The target of the study was detection of the protective and improving role of EPO against MTX provoked toxic renal injury in male rats.

Materials and Methods

Animals

Sixty adult male albino rats of body weight about 200-250 g were obtained from animal house, Jeddah, KSA. They were housed at the animal house at 21-22°C in a 12/12 hours light/dark cycle, fed a standard rat chow and given free access to water.

Experimental design

The rats were housed in the animal housing facility of the laboratory of experimental surgery and surgical research, medical college, Taif University, in a controlled environment. The permission of animal use in our study was obtained from Taif University that supported this research. All conditions follow normal and standards laboratory circumstances (21) including cages and the environment with 55% relative humidity, central ventilation (15 air changes/h), a temperature of 20°C ± 2°C and artificial 12-hour light-dark cycle. After two weeks of acclimatization period, the animals were equally divided into three groups (each involved 20 rats). All groups were maintained on standard chow diet for 9 weeks:

Group 1: Animals were served as control and treated with intraperitoneal injections of normal saline at a dosage of 0.5 mg/kg BW twice weekly for the total duration of 9 weeks.

Group 2: Animals were injected with MTX hydrate intraperitoneal twice weekly at a dosage of 0.5 mg/kg BW for the total duration of 9 weeks.

Group 3: Animals were injected with MTX hydrate intraperitoneal twice weekly at a dosage of 0.5 mg/kg BW for 9 weeks concomitant with subcutaneous injections of 100 IU/kg recombinant human EPO (rhEPO) once weekly for 9 weeks (total of 9 injections).

At the end of the experiment, blood and urinary
samples were collected to measure concentrations of serum (S) creatinine and serum urea as well as urinary microalbuminuria to assess renal function. Blood and urine samples were measured as follows:

- Blood urea level (mg/dL) by the enzymatic method (modified Berthelot reaction) (dp international; Tuscaloosa, USA).
- Serum creatinine level (mg/dL) by a colorimetric kinetic method (Bio-diagnostic; Paterson, New Jersey, United States).
- Albumin in urine (mg/dL) by Folin–Lowry Colorimetric Method (Bio-diagnostic; Paterson, New Jersey, United States).

Lastly, all rats belonging to the three groups were sacrificed by the overdose of anesthesia. From each rat, autopsy renal specimens were excised and washed several times with normal saline, immediately fixed in 10% neutral buffered formalin. After proper fixation, the specimens were washed in tap water, dehydrated in serial ethyl alcohol, cleared in xylol, embedded and cast in paraffin. Thin paraffin sections (3-4 microns) were prepared, put on charged glass slides and stained with hematoxylin and eosin for general morphological examination and detection of the histopathological changes, Mallory’s trichrome for detection of collagen fibers and Periodic Acid Schiff (PAS) with diastase for detection of glycogen content of renal tubular lining cells and basement membranes of the renal parenchymal structures (23).

Ethical issues
The experimental protocol was approved in advanced by Taif University Ethics Committee (Code # 21974). The research followed the tenets of the Declaration of Helsinki. The protocol of this study is also designed in accordance with the ethical principles of the International Committees for the Protection of Animal Rights Laboratory.

Statistical analysis
Data were collected and analyzed using SPSS software package version 17. Quantitative data were analyzed using F-test (ANOVA) to compare the different groups. Pearson’s coefficient was used to estimate the correlation between different parameters. Additionally, $P$ values derived from least significant difference (LSD) test $\leq 0.05$ was assumed to be significant.

Results
Table 1 and its chart (Figure 1) showed insignificant statistical differences in the mean values of all renal function biochemically analyzed substances in the MTX-EPO-managed group (G3) when compared to the control group (G1) ($P > 0.05$). However, the MTX-treated group (G2) revealed marked nephrotoxicity indicated by a highly statistically significant increase in the mean values of serum urea and creatinine as well as of urine albumin level ($P < 0.05$) when matched to the control group. On the contrary, the third group displayed a highly statistical significant decrease in the mean values of serum urea and creatinine as well as of urine albumin level ($P < 0.05$) when challenged with the second group.

Microscopically, the control renal sections revealed normal parenchymal tissue including renal glomeruli and renal tubules that possessed regular lumen and lined by cubical epithelial cells (Figure 2-G1). However, in group 2, MTX caused degeneration of renal tubules and disruption of their basement membranes. The majority of renal tubules showed a cystic luminal dilatation and flattened epithelial cell lining. Moreover, the glomeruli were degenerated (Figure 2-G2). In addition, markedly reduced toxic renal structural changes were noticed in the group 3 renal sections administrated EPO concomitant with MTX. Improved histopathological changes detected in group 3 were evidenced by morphological return nearly back to the normal appearance of the control group except for mildly dilated few renal tubules (Figure 2-G3).

In addition, periodic acid-Schiff (PAS) with diastase stain displayed a strong eosinophilic cytoplasmic reaction within the renal tubular lining cells as well as integrity of tubular basement membranes in both control (Figure 3-G1) and third (Figure 3-G3) groups regarding apparently disrupted tubular basement membranes in the group 2 despite a morphologically unremarkable change in the glycogen content within its lining cells (Figure 3-G2).

Furthermore, Mallory’s trichrome stain showed a normally distributed collagen in the renal parenchymal tissue together with intact renal tubular and glomerular basement membranes as well as an intact glomerular Bowman’s capsule in the control group (Figure 4-G1).

<table>
<thead>
<tr>
<th>Analyzed substances</th>
<th>Groups</th>
<th>$P$ value (G1-G2)</th>
<th>$P$ value (G1-G3)</th>
<th>$P$ value (G2-G3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum urea (mg/dL)</td>
<td>40.27± 5.149</td>
<td>65.89± 8.65</td>
<td>41.05± 1.78</td>
<td>0.0001</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>4.32 ± 0.137</td>
<td>4.57 ± 0.524</td>
<td>1.34 ± 0.259</td>
<td>0.0001</td>
</tr>
<tr>
<td>Urine albumin (mg/dL)</td>
<td>25.39 ± 6.081</td>
<td>42.35 ± 9.226</td>
<td>28.46 ± 5.042</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

$P$ values were derived from LSD test.

Table 1. Results of biochemically analyzed substances in all groups

158 Journal of Nephropharmacology, Volume 7, Number 2, July 2018 http://www.jnephropharmacology.com
However, relatively increased collagen fibers both in the glomeruli and around the renal tubules together with disrupted both glomerular and tubular basement membranes were detected in the group 2 (Figure 4-G2). In group 3 (Figure 4-G3), the structural changes observed in the group 2 were ameliorated and came nearly back to the normal appearance detected in the control group.
Discussion

The main indicators of renal function are creatinine and blood urea nitrogen (BUN) that are catabolic protein products chiefly metabolized by the kidney. When the renal function is disturbed beyond its compensatory capacity, the BUN and serum creatinine levels are apparently increased. As mentioned before, the administration of HDMTX is essential in oncotherapy of several childhood and adulthood cancers and can be safely used with leucovorin in normal renal function patients following alkalization and hydration tools. However, renal dysfunction with HDMTX administration even with these protective tools is seen with chemotherapy of patients having osteosarcoma (7). Our study aimed at prevention and amelioration of MTX-induced nephrotoxicity to avoid potentially life-threatening MTX-associated toxicities stated by Widemann and Adamson particularly bone marrow suppression and mucocutaneous as well as hepatic inflammation (7). We displayed variable renal parenchymal structural changes associated with significantly increased serum urea and creatinine together with elevated urinary albumin levels in the treated group with MTX. The structural changes included degeneration of renal tubules and glomeruli, disruption of their basement membranes and relatively increased collagen fibers both peritubular and in the glomeruli. In addition, the majority of renal tubules showed a cystically dilated lumen with flattening of their lining epithelial cells irrespective of unremarkably changed glycogen content observed within its lining cells. These findings coincided with those detected by Sharba et al who stated that the amount of oncotherapeutic drug in the tubular cells of the kidney exceeds several times its amount in the extracellular compartment and its major uptake occurs in the proximal renal tubules (24). In addition, Liao et al found a significant rise in both blood BUN and creatinine levels in the ischemic rat kidney at 4, 12 and 24 hours following renal reperfusion and they indicated a damage of the renal parenchymal tissue after reperfusion of ischemia so that the renal excretory capacity of urea nitrogen and creatinine was largely diminished (16).

Smeland et al together with Messmann and Allegra stated that MTX-induced renal nephrotoxicity occurs due to either renal tubular precipitation of the drug or its metabolites or direct renal tubular damaging effect of the drug (25,26). Furthermore, Rjiba-Touati et al documented that drug-induced nephrotoxicity is due to accumulation of toxic free radicals associated with renal tubular cellular damage by lipid peroxidation process (27). Additionally, Widemann and Adamson mentioned that the majority of MTX is removed from the human body via the urine and the drug and its metabolites are weakly soluble in acidic urine, therefore, parenteral administration of HDMTX in a short duration is accompanied by elevated drug concentration both in blood and urine with subsequent higher risk of development of the renal dysfunction (7).

Watowich suggested that EPO has a paracrine role and detected EPO receptor which is encoded by messenger RNA in many tissues involving the renal one (28). In our study, EPO co-administrated with MTX markedly reduced the abnormal toxic renal structural and biochemical changes noticed in the group 3. This group revealed improvement of histopathological changes involving the extent of collagen fibers in the glomeruli and around the renal tubules that nearly returned back to the normal appearance of the control one apart from mildly dilated renal tubules. Additionally, the biochemical renal analyzed group 3 findings were significantly declined to approximate those of control normal one (28). Our results simulated those of Liao et al who found a decrease of BUN and serum creatinine levels in EPO-treated group of rats within 4, 12 and 24 hours following renal reperfusion than their values in rat group having renal ischemic injury and therefore, they confirmed the defensive EPO effect on the renal ischemia. In addition, they verified that the pathologic renal ischemic changes have been attributed to renal cellular apoptosis, endothelial injury of the renal vessels, oxidative stress of the renal tissue and the inflammatory reaction within the kidney (16). Our group 3 results were identical to those of Zafirov et al who distinguished a decreased proteinuria in the group of rats treated with EPO which exerted its renoprotective action due to an induction of proliferative and regenerative capacities of the tubular cells and consequently avoid the renal damaging effect of cisplatin drug (29). Additionally, Yang et al stated that EPO may act as an anti-apoptotic factor through suppression of both apoptosis-inducing factor and apoptosis protease-activating factor-1 (30).

Hassan et al mentioned that EPO after binding to its receptor can enhance various genes transcription, thus, acting as a survival agent and they, as well, discovered an ameliorated kidney function in the group of diabetic rats given EPO (31). Similarly, Toba et al established the renoprotective EPO action through the improvement of proteinuria, impaired renal function and renal fibrosis of the diabetic rats after chronic management with a low EPO dosage (32). Identically, Pallet et al (33) stated that the anti-apoptotic function of EPO is evidenced by the production of anti-apoptotic proteins of the Bcl-2 family like Bcl-2 and Bcl-x (L) which interfered with tubular epithelial lining cell death and consequently resulted in an enhancement of tubular epithelial cell regeneration and elicited the retrieval of kidney function as declared by Sharples and Yaqoob (34). Furthermore, Vesey et al suggested that EPO could exert its anti-apoptotic property in both ischemic renal and hypoxic circumstances (14).

The renoprotective effect of EPO is verified by Baek et al, Brochner et al, Khalid et al who detected an excessive
release of interleukins and tumor necrosis factor in case of IRI both in local renal tissue and generalized in the blood and interpreted that EPO diminished the contents of these inflammatory mediators in both locations through extrahematopoietic inhibitory action of EPO on the release of these mediators (35-37). Additionally, as mentioned before, Lee et al (38); O’Neill et al (39), Chen et al (40), Ozbilgin et al (41), and Liao et al (16) confirmed that ischemic perfusion of the kidney was associated with local (in the renal tissue) overexpressed TLR4 receptor which triggers NK-kb and local overexpressed NF-kB protein receptor that enhances the interleukins and tumor necrosis factor transcriptions and they accounted that the expression of these inflammatory mediators was suppressed with EPO management indicating that EPO could minimize the synthesis of these mediators through inhibition of the TLR4/NFkB pathway.

Besides, our third group results were in accordance to those of Rjiba-Touati et al who mentioned that the administration of EPO prior to, coincident with or subsequent to cisplatin treatment had improved cisplatin-induced nephrotoxicity via the reduction of an impaired renal function which was induced by this chemotherapeutic drug. They pointed this improvement to the EPO antioxidant action that could eradicate oxygen free radicals responsible for the oxidative stress of renal tissue (27).

Kumral et al mentioned that EPO, besides its anti-inflammatory character, activated the antioxidant enzymes and thus inhibited the production of nitric oxide and diminished lipid peroxidation (42).

Zhang et al affirmed that transcriptional hypoxia-inducible factor-1a is responsible for adaptation of the cells to a decreased oxygen pressure. It controls the genes correlated to neovascularization, cell proliferation and cell survival in addition to genes related to iron and glucose metabolism (43). Moreover, Park et al discovered that EPO has a protective role to diminish the renal fibrosis in mice via inhibition of transforming growth factor beta (44). Finally, Schiffer et al demonstrated that EPO prevents the development of glomerular fibrosis through a direct ameliorating effect on its podocyte damage (45).

Conclusion
In conclusion, our study confirmed the renoprotective and ameliorating roles of EPO on both structure and function of the male Albino rat nephrotoxicity induced by MTX drug. Therefore, supplementation of EPO is essential concomitant with MTX chemotherapy.

Recommendations
First, future studies on a wider scale have to be carried out in renal toxicity induced by various chemotherapeutic drugs on various animal models to confirm the protective and therapeutic effects of EPO. Second, EPO, that is greatly safe, cheap and available drug, can be attempted on human MTX-induced nephrotoxicity.

Acknowledgments
At first, we would like to express our deep thanks and gratitude to Taif University, KSA research Deanship for their financial support of our project to its end. We would like also to present our thankfulness and gratitude to Mr. Gamal Abdullah (Microscopic Technician) for his help and follow up of this research. Our thankfulness and gratitude are extended also to Faisal Faheed Alsobaiti (Medical Resident in Department of Internal Medicine, King Faisal Hospital) and to Wissam Khalil Haider Almanadili, Ammar Saud Jamaan Altowairqi and Abdullah Ayesh Abdullah Altalhi (Undergraduate students, College of Medicine, Taif University) for their help in the final stage of this work.

Authors’ contribution
AHAR suggested and implemented the title of the research. Moreover, AHAR together with KEH and AIA were responsible for histopathological renal tissue section preparation, staining and diagnosis as well as evaluation of the renal normal and abnormal structural findings. RRS and MHW were responsible for follow up the groups of rats, administrated the drugs for the groups and sacrificed the animals and excised their kidneys. AAA and GME were responsible for the biochemical analysis and evaluation of the renal function in all groups. Finally, all authors participated in the editing of the original research.

Conflicts of interest
The authors declare no conflict of interest.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support
According to the rules of research system of Taif University, Our University funded the purchase of the required animals, materials, stains and biochemical kits.

References


Erythropoietin and methotrexate nephrotoxicity


